WHO says aspartame is a ‘possible carcinogen.’ The FDA disagrees

The World Health Organization (WHO) has classified aspartame, a common artificial sweetener, as a “possible carcinogen,” drawing disagreement from the U.S. Food and Drug Administration (FDA).

The big picture: The WHO’s announcement is based on a review of “limited evidence” and does not alter the recommended daily intake of aspartame.
* The WHO advises that “high consumers” of diet soda or other foods containing aspartame should be cautious.
* According to the WHO, a person weighing about 130 pounds could consume up to 2,400 milligrams per day of aspartame, which is roughly equivalent to 12 cans of Diet Coke.

Dispute over findings: The U.S. FDA disagrees with the WHO’s new classification of aspartame as possibly carcinogenic.
* The FDA argues that this new label does not mean that aspartame is conclusively linked to cancer.
* Two separate WHO committees reviewed the evidence on aspartame, with one finding a limited evidence of potential cancer risk, while the other concluding that the association was not convincing.

Industry Defense: The American Beverage Association, representing companies like Coca-Cola, PepsiCo, and Keurig Dr Pepper, maintains that aspartame is safe.
* The association cites the WHO’s decision to maintain the current acceptable daily intake as support for the FDA’s position.

Despite uncertainties: Some experts argue that diet sodas can be useful for those trying to manage their weight and limit sugar intake.
* While the WHO advises against using non-sugar sweeteners for weight control, other studies show that swapping caloric drinks for zero-calorie options can be beneficial.
* However, others are calling for more in-depth, long-term research, given the potential decades-long period for cancers to develop after exposure to possible carcinogens.

View original article on NPR

This summary was created by an AI system. The use of this summary is subject to our Terms of Service.

Contact us about this post

Posted

in

by

Tags:

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *